7 news items
Halozyme's ENHANZE Product Gets New Patent Grant in EU
ABBV
ABOS
ALXO
6 Jun 24
and sustained revenues from this partnership.
For other ENHANZE licenses, Halozyme does not expect the new patent to impact the existing
Takeda Presents Phase 2b Results for Narcolepsy Treatment at SLEEP 2024
TAK
3 Jun 24
with NT1 demonstrated statistically significant and clinically meaningful improvements across primary and secondary endpoints, with efficacy sustained
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
meaningful improvements across primary and secondary endpoints, with efficacy sustained over 8 weeks of treatment
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other
1owf77jwk5xby3xg2llhyrwg4vra7
TAK
9 May 24
-term impact of generic competition to return to sustainable revenue and profit growth beginning in FY2025
8yevm7x77fu3nggmzxat6bl56hxxinxcxgknyv2
TAK
26 Apr 24
to have enhanced selectivity that limits off-target kinase activity, allowing for high drug exposure, sustained target inhibition, and flexibility
- Prev
- 1
- Next